Phase II trial of paclitaxel and granulocyte colony-stimulating factor-in patients with pancreatic carcinoma: A southwest oncology group study

被引:63
作者
Whitehead, RP
Jacobson, J
Brown, TD
Taylor, SA
Weiss, GR
Macdonald, JS
机构
[1] TEXAS TECH UNIV,HLTH SCI CTR,LUBBOCK,TX 79430
[2] SW ONCOL GRP,CTR STAT,SEATTLE,WA
[3] HEMATOL ONCOL CONSULTANTS TIDEWATER,NORFOLK,VA
[4] UNIV KANSAS,MED CTR,KANSAS CITY,KS 66103
[5] UNIV TEXAS,HLTH SCI CTR,SAN ANTONIO,TX
[6] TEMPLE UNIV,PHILADELPHIA,PA 19122
关键词
D O I
10.1200/JCO.1997.15.6.2414
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: pancreatic cancer is difficult to treat, with most patients surgically unresectable at the time of diagnosis, Radiotherapy and chemotherapy can offer palliation, but more effective therapy is needed, This trial evaluated the effects of an aggressive schedule of paclitaxel given with granulocyte colony-stimulating factor (G-CSF) to patients with advanced pancreatic cancer, Patients and Methods: All patients were required to have a histologic diagnosis of pancreatic adenocarcinoma with measurable disease and no prior chemotherapy or radiation therapy, Patients had to have performance status of 0 to 2, pretreatment absolute granulocyte count greater than or equal to 1,500/mu L, and platelet count greeter than or equal to the institutional lower limit of normal, Following pretreat ment with dexamethasone, diphenhydramine, and cimetidine, patients received paclitaxel at a dose of 250 mg/m(2) by 24-hour infusion an day 1, repeated every 21 days. G-CSF was given at a dose of 5 mu g/kg/d on days 3 to 18 or until two consecutive absolute neutrophil counts (ANCs) greater than or equal to 10,000/mu L were obtained, Doses of paclitaxel were modified depending on nadir counts, Results: Forty-five patients were entered onto this study, with six ineligible, For the 39 eligible patients, there was one complete response (CR) and two partial responses (PRs), five stable/no responses, 23 increasing disease, two early deaths, and six patients whose assessment was inadequate to determine response, The response rate was therefore three of 39 or 8% (95% confidence interval [CI], 2% to 21%). The median survival time for the 39 eligible patients was 5 months, The most common toxicities were anemia, leukopenia/granulocytopenia, malaise/fatigue, nausea/vomiting, alopecia, thrombocytopenia, paresthesias, and liver function abnormalities, There was one death due to sepsis, Conclusion: Single-agent paclitaxel in this dose and schedule has minimal activity in pancreatic adenocarcinoma patients. (C) 1997 by American Society of Clinical Oncology.
引用
收藏
页码:2414 / 2419
页数:6
相关论文
共 29 条
[11]  
KELSEN D, 1994, SEMIN ONCOL, V21, P44
[12]   DOSE-INTENSE TAXOL - HIGH RESPONSE RATE IN PATIENTS WITH PLATINUM-RESISTANT RECURRENT OVARIAN-CANCER [J].
KOHN, EC ;
SAROSY, G ;
BICHER, A ;
LINK, C ;
CHRISTIAN, M ;
STEINBERG, SM ;
ROTHENBERG, M ;
ADAMO, DO ;
DAVIS, P ;
OGNIBENE, FP ;
CUNNION, RE ;
REED, E .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (01) :18-24
[13]  
LINK CJ, 1994, BLOOD, V83, P1188
[14]  
Loffler TM, 1996, SEMIN ONCOL, V23, P32
[15]   Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer [J].
McGuire, WP ;
Hoskins, WJ ;
Brady, MF ;
Kucera, PR ;
Partridge, EE ;
Look, KY ;
ClarkePearson, DL ;
Davidson, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (01) :1-6
[16]  
MOORE M, 1995, P AN M AM SOC CLIN, V14, P199
[17]  
OMURA GA, 1996, P AN M AM SOC CLIN, V15, P280
[18]  
Parker S. L., 1996, CA CANC J CLIN, V65, P5
[19]  
ROTH BJ, 1993, CANCER, V72, P2457, DOI 10.1002/1097-0142(19931015)72:8<2457::AID-CNCR2820720825>3.0.CO
[20]  
2-Z